Caitlin Ray
A5020326288- Vaccine Coverage and Hesitancy
- SARS-CoV-2 and COVID-19 Research
- Influenza Virus Research Studies
- Respiratory viral infections research
- Bacterial Infections and Vaccines
- COVID-19 Clinical Research Studies
- COVID-19 and healthcare impacts
- Viral gastroenteritis research and epidemiology
- COVID-19 epidemiological studies
National Center for Immunization and Respiratory Diseases
2023-2024
Centers for Disease Control and Prevention
2023-2024
Intermountain Healthcare
2023
AID Atlanta
2023
Kaiser Permanente Center for Health Research
2023
Regenstrief Institute
2023
During June-October 2022, the SARS-CoV-2 Omicron BA.5 sublineage accounted for most of sequenced viral genomes in United States, with further diversification through November 2022.* Bivalent mRNA vaccines contain an ancestral strain component plus updated BA.4/BA.5 sublineages. On September 1, a single bivalent booster dose was recommended adults who had completed primary vaccination series (with or without subsequent doses), last administered ≥2 months earlier (1). 13-November 18, VISION...
On September 1, 2022, CDC's Advisory Committee on Immunization Practices (ACIP) recommended a single bivalent mRNA COVID-19 booster dose for persons aged ≥12 years who had completed at least monovalent primary series. Early vaccine effectiveness (VE) estimates among adults ≥18 showed receipt of provided additional protection against COVID-19-associated emergency department and urgent care visits hospitalizations compared with that in received only doses (1); however, insufficient time...
During June-October 2022, the SARS-CoV-2 Omicron BA.5 sublineage accounted for most of sequenced viral genomes in United States, with further diversification through November 2022.* Bivalent mRNA vaccines contain an ancestral strain component plus updated BA.4/BA.5 sublineages. On September 1, a single bivalent booster dose was recommended adults who had completed primary vaccination series (with or without subsequent doses), last administered ≥2 months earlier (1). 13-November 18, VISION...
Abstract Background We describe prescribing and dispensing patterns of influenza antivirals among patients with laboratory-confirmed within U.S. urgent care emergency department settings. Methods A retrospective cross-sectional study was conducted for encounters from four large, integrated health systems participating in the VISION network adult presenting acute respiratory illness to cares or departments positive virus test results during 2023–2024 season. The analysis restricted at higher...
Abstract Background The 2022–2023 United States influenza season had unusually early activity with high hospitalization rates. Vaccine-matched A(H3N2) viruses predominated, lower levels of A(H1N1)pdm09 also observed. Methods Using the test-negative design, we evaluated vaccine effectiveness (VE) during against A–associated emergency department/urgent care (ED/UC) visits and hospitalizations from October 2022 to March 2023 among adults (aged ≥18 years) acute respiratory illness (ARI). VE was...
The 2023-2024 influenza season had predominant A(H1N1)pdm09 virus activity, but A(H3N2) and B viruses co-circulated. Seasonal vaccine strains were well-matched to these viruses.
ABSTRACT Background Although psychiatric disorders have been associated with reduced immune responses to other vaccines, it remains unknown whether they influence COVID‐19 vaccine effectiveness (VE). This study evaluated risk of hospitalization and estimated mRNA VE stratified by disorder status. Methods In a retrospective cohort analysis the VISION Network in four US states, rate laboratory‐confirmed COVID‐19‐associated between December 2021 August 2022 was compared across diagnoses...
Abstract Adults with disabilities are at increased risk for severe coronavirus disease 2019 (COVID-19). Using data across 9 states during Delta- and Omicron-predominant periods (June 2021–September 2022), we evaluated the effectiveness of original monovalent COVID-19 messenger RNA vaccines among 521 206 emergency department/urgent care encounters (11 471 [2%] in patients a documented disability) 139 548 hospitalizations (16 569 [12%] laboratory-confirmed illness adults (aged ≥18 years)....